Pharma Collaborations:
Advancing Companion Diagnostics
ISET® technology provides a highly sensitive, non-invasive platform for developing companion diagnostics to targeted therapies.
It enables circulating tumor cells immunolabelling characterization and direct analysis of tumor DNA from both intact circulating tumor cells (CTCs) and ctDNA, empowering precision medicine from the very early cancer stages.
Why Partner with Rarecells?
- Unparalleled Sensitivity:
Detects as few as a single CTC in 10 mL of blood, with >95% CE-validated sensitivity — ideal for early cancer and MRD (minimal residual disease) monitoring - Versatile and Proven:
- Validated in 120+ peer-reviewed studies, ISET® shows high reproducibility across all major solid tumors.
- Compatible with standard molecular targets — including EGFR, KRAS, BRAF, ALK, and HER2 — it integrates seamlessly into existing ctDNA workflows.
- Real-Time Tumor Intelligence:
Provides morphological and molecular data from live tumor cells, enabling patient stratification, therapy response assessment, and resistance tracking. - Scalable Solution: ISET® isolates whole, intact CTCs from stabilized blood collected in standard Streck tubes, maintaining sample integrity for up to 72 hours post-collection — a key differentiator from other CTC platforms.
- Comprehensive Genomics:
ISET® uniquely enables simultaneous analysis of ctDNA and CTC-DNA within a single workflow, offering the most complete genomic view of tumor heterogeneity to accelerate companion diagnostic development.
Let’s advance companion diagnostics together.
Contact Us: contact@rarecells.com